All In Biotech

Drug Trial Radar · NCT06586112

A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis

A Multicenter, Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis (ONWARD1)

Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 912 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

912

Actual

Start

Jul 25, 2024

Primary completion

Sep 19, 2025

Study completion Nov 20, 2025

Sponsor

Lead sponsor
Alumis IncIndustry
Sponsor type
Industry
First posted
Sep 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if ESK-001 works to treat moderate to severe plaque psoriasis. The main questions it aims to answer are: * Does ESK-001 reduce the severity of people's psoriasis? * How safe is ESK-001 in people with moderate to severe plaque psoriasis? The study includes 2 comparators: a placebo control (a 'dummy' tablet that does not contain the medicine ESK-001 but looks just like it) and an active control (apremilast, which is a medicine approved to treat psoriasis). People taking part in this study must be men or women aged at least 18 years and have had plaque psoriasis for at least 6 months, currently moderate to severe. Participants will: * take drug every day for 24 weeks. * visit the clinic for checkups and tests. * fill out questionnaires about their psoriasis, itch severity, and change in quality of life. * be assessed for health issues and side effects, physical examinations, vital signs, heart electrical activity measurements, and psychological health. * provide blood and urine samples.

Conditions

  • Plaque Psoriasis

Interventions

  • EnvudeucitinibDrug

    ESK-001

  • ApremilastDrug

    Apremilast

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To determine whether ESK-001 reduces the severity of psoriasis by 75% (using the PASI) or by at least 2 points (using sPGA score) compared to placeboTime frame: 16 weeks

Locations

156 sites in 10 countries. Site status is shown where the registry gives one.

  • Alliance Dermatology

    Phoenix, Arizona

  • Scottsdale Clinical Trials

    Scottsdale, Arizona

  • Northwest Arkansas Clinical Trials Center (NWACTC), PLLC

    Rogers, Arkansas

  • Exalt Clinical Research

    Chula Vista, California

  • California Dermatology & Clinical Research Institute

    Encinitas, California

  • First OC Dermatology Research Inc

    Fountain Valley, California

  • Marvel Clinical Research, LLC

    Huntington Beach, California

  • Sunwise Clinical Research, LLC

    Lafayette, California

  • Wallace Medical Group Inc

    Los Angeles, California

  • Northridge Clinical Trials - Elite Clinical Network

    Northridge, California

  • Pasadena Clinical Trials

    Pasadena, California

  • Therapeutics Clinical Research

    San Diego, California

  • Unison Clinical Trials/ Shahram Jacobs MD

    Sherman Oaks, California

  • Olive View - UCLA Education & Research Institute

    Sylmar, California

  • California Dermatology Institute - Thousand Oaks

    Thousand Oaks, California

  • Clearlyderm Dermatology - West Boca Raton

    Boca Raton, Florida

  • Driven Clinical Research

    Coral Gables, Florida

  • Jacksonville Center for Clinical Research

    Jacksonville, Florida

  • Glick Skin Institute - Margate

    Margate, Florida

  • San Marcus Research Clinic, Inc - Miami

    Miami Lakes, Florida

  • Savin Medical Group LLC

    Miami Lakes, Florida

  • Oceanic Research Group

    North Miami Beach, Florida

  • LENUS Research

    Sweetwater, Florida

  • Caban Skin Institute

    Tampa, Florida

  • ForCare Medical Center

    Tampa, Florida

  • Skin Care Physicians of Georgia - Warner Robins

    Macon, Georgia

  • MetroMed Clinical Trials

    Chicago, Illinois

  • Arlington Dermatology

    Rolling Meadows, Illinois

  • NorthShore Medical Group - Dermatology - Skokie

    Skokie, Illinois

  • Dundee Dermatology

    West Dundee, Illinois

  • Dawes Fretzin Clinical Research Group

    Columbus, Indiana

  • The South Bend Clinic

    South Bend, Indiana

  • Equity Medical - Bowling Green

    Bowling Green, Kentucky

  • Velocity Clinical Research at The Dermatology Clinic, Baton Rouge

    Baton Rouge, Louisiana

  • Tulane University School of Medicine

    New Orleans, Louisiana

  • MetroBoston Clinical Partners

    Brighton, Massachusetts

  • Cleaver Dermatology

    Kirksville, Missouri

  • OptiSkin

    New York, New York

  • The Ohio State University Wexner Medical Center (OSUWMC) - OSU Dermatology East - Columbus

    Gahanna, Ohio

  • Dermatologists of Southwestern Ohio, LLC

    Mason, Ohio

Showing 40 of 156 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.